The discovery of a class of novel HIV-1 maturation inhibitors and their potential in the therapy of HIV

Expert Opinion on Investigational Drugs

Volumn 14, Issue 6, 2005, Pages 681-693

  Yu, Donglei ^a   Wild, Carl T ^b   Martin, David E ^b   Morris Natschke, Susan L ^a   Chen, Chin Ho ^c   Allaway, Graham P ^b   Lee, Kuo Hsiung ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b VI Technologies   (United States)

^c DUKE UNIVERSITY   (United States)

Author keywords

Anti HIV; Betulinic acid derivatives; DSB; Maturation inhibitors; PA 457; Triterpenes

Indexed keywords

3 (3',3' DIMETHYLGLUTARYL)BETULINIC ACID; 3 O (3',3' DIMETHYLSUCCINYL)DIHYDROBETULINIC ACID; 3 O (3,3 DIMETHYLSUCCINYL)BETULIC ACID; 3,28 DI(3',3' DIMETHYLGLUTARYL)BETULIN; 4 (8 BETULINOYLAMINOOCTANOYLAMINO) 3 HYDROXY 6 METHYLHEPTANOIC ACID; ANTIVIRUS AGENT; BETULIC ACID; BETULIN; BETULINYLGLYCINE; CAPSID PROTEIN; DIHYDROBETULINIC ACID; ENFUVIRTIDE; GAG PROTEIN; INDINAVIR; NEVIRAPINE; PLATANIC ACID; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR; UNCLASSIFIED DRUG; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; CLINICAL TRIAL; CONCENTRATION RESPONSE; CYTOTOXICITY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; REVIEW; STRUCTURE ACTIVITY RELATION; VIRUS CAPSID; VIRUS LOAD;

ANIMALS; ANTI-HIV AGENTS; DRUGS, INVESTIGATIONAL; HIV INFECTIONS; HIV-1; HUMANS; TRITERPENES;

EID: 21244493601     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.14.6.681     Document Type: Review

References (60)

1. PANI A, LOI AG, MURA M, MARCEDDU T, LA COLLA P, MARONGIU ME: Targeting HIV: old and new players. Curr. Drug Targets Infect. Disord. (2002) 2:17-32.
2. MILLER MD, HAZUDA DJ: New antiretroviral agents: looking beyond protease and reverse transcriptase. Curr. Opin. Microbiol. (2001) 4:535-539.
3. MOORE JP, STEVENSON M: New targets for inhibitors of HIV-1 replication. Nat. Rev. Mol. Cell Biol. (2000) 1:40-49.
4. FUNG HB, GUO Y: Enfuvirtide: a fusion inhibitor for the treatment of HIV infection. Clin. Ther. (2004) 26:352-378.
5. STEPHENSON J: The art of 'HAART': researchers probe the potential and limits of aggressive HIV treatments. JAMA (1997) 277:614-616.
6. KLEIN MB, WILLEMOT P, MURPHY T, LALONDE RG: The impact of initial highly active antiretroviral therapy on future treatment sequences in HIV infection. AIDS (2004) 18:1895-1904.
7. LUCAS GM, CHAISSON RE, MOORE RD: Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann. Intern. Med. (1999) 131:81-87.
8. LEE K-H: Current developments in the discovery and design of new drug candidates from plant natural product leads. J. Nat. Prod. (2004) 67:273-283.
9. CONNOLLY JD, HILL RA: Triterpenoids. Nat. Prod. Rep. (2001) 18:560-578.
10. HUANG L, CHEN CH: Molecular targets of anti-HIV-1 triterpenes. Curr. Drug Targets Infect. Disord. (2002) 2:33-36.
11. DE CLERCQ E: Current lead natural products for the chemotherapy of human immunodeficiency virus (HIV) infection. Med. Res. Rev. (2000) 20:323-349.
12. HIRABAYASHI K, IWATA S, MATSUMOTO H et al.: Antiviral activities of glycyrrhizin and its modified compounds against human immunodeficiency virus Type 1 (HIV-1) and herpes simplex virus Type 1 (HSV-1) in vitro. Chem. Pharm. Bull. (1991) 39:112-115.
13. MAYAUX JF, BOUSSEAU A, PAUWELS R et al.: Triterpene derivatives that block entry of human immunodeficiency virus Type 1 into cells. Proc. Natl. Acad. Sci. USA (1994) 91:3564-3568.
14. SOLER F, POUJADE C, EVERS M et al.: Betulinic acid derivatives: a new class of specific inhibitors of human immunodeficiency virus type 1 entry. J. Med. Chem. (1996) 39:1069-1083.
15. HOLZ-SMITH SL, SUN IC, JIN L, MATTHEWS TJ, LEE KH, CHEN CH: Role of human immunodeficiency virus (HIV) Type 1 envelope in the anti-HIV activity of the betulinic acid derivative IC-9564. Antimicrob. Agents Chemother. (2001) 45:60-66.
16. YUAN X, HUANG L, HO P, LABRANCHE C, CHEN CH: Conformation of gp120 determines the sensitivity of HIV-1 DH012 to the entry inhibitor IC-9564. Virology (2004) 324:525-530.
17. SAHU NP: Triterpenoid saponins of Mimusops elengi. Phytochemistry (1996) 41:883-886.
18. EL-MEKKAWY S, MESELHY MR, NAKAMURA N et al.: Anti-HIV- 1 and anti-HIV-1-protease substances from Ganoderma lucidum. Phytochemistry (1998) 49:1651-1657.
19. XU H-X, MING D-S, DONG H, BUT PP-H: A new anti-HIV triterpene from Geum japonicum. Chem. Pharm. Bull. (2000) 48:1367-1369.
20. EVERS M, POUJADE C, SOLER F et al.: Betulinic acid derivatives: a new class of human immunodeficiency virus type-1-specific inhibitors with a new mode of action. J. Med. Chem. (1996) 39:1056-1068.
21. KASHIWADA Y, HASHIMOTO F, COSENTINO LM, CHEN C-H, GARRETT PE, LEE K-H: Betulinic acid and dihydrobetulinic acid derivatives as potent and-HIV agents. J. Med. Chem. (1996) 39:1016-1017.
22. KANAMOTO T, KASHIWADA Y, KANBARA K et al.: Anti-human immunodeficiency virus activity of YK-FH312 (a betulinic acid derivative), a novel compound blocking viral maturation. Antimicrob. Agents Chemother. (2001) 45:1225-1230.
23. LI F, GOILA-GAUR R, SALZWEDEL K et al.: PA-457: A potent HIV inhibitor that disrupts core condensation by targeting a late step in Gag processing. Proc. Natl. Acad. Sci. USA (2003) 100:13555-13560.
24. FUJIOKA T, KASHIWADA Y, KILKUSKIE RE et al.: Anti-AIDS agents, 11. Betulinic acid and platanic acid as anti-HIV principles from Syzigium claviflorum, and the anti-HIV activity of structurally related triterpenoids. J. Nat. Prod. (1994) 57:243-247.
25. HASHIMOTO F, KASHIWADA Y, COSENTINO LM, CHEN C-H, GARRETT PE, LEE K-H: Anti-AIDS agents 27. Synthesis and anti-HIV activity of betulinic acid and dihydrobetulinic acid derivatives. Bioorg. Med. Chem. (1997) 5:2133-2143.
26. KASHIWADA Y, WANG HK, NAGAO T et al.: Anti-AIDS agents. 30. Anti-HIV activity of oleanolic acid, pomolic acid, and structurally related triterpenoids. J. Nat. Prod. (1998) 61:1090-1095.
27. CICHEWICZ RH, KOUZI SA: Chemistry, biological activity, and chemotherapeutic potential of betulinic acid for the prevention and treatment of cancer and HIV infection. Med. Res. Rev. (2003) 24:90-114.
28. SINGH SS, PATRO B, TRIPATHI V, SRIVASTAVA A, PANDEY SC, GHOSH AC: Betulinic acid and its pharmacological activity - a review. J. Med. Aromatic Plant Sci. (2002) 24:1031-1037.
29. YUN Y, HAN S, PARK E et al.: Immunomodulatory activity of betulinic acid by producing pro-inflammatory cytokines and activation of macrophages. Arch. Pharm. Pes. (2003) 26:1087-1095.
30. LABROSSE B, TREBOUTE C, ALIZON M: Sensitivity to a nonpeptidic compound (RPR-103611) blocking human immunodeficiency virus type 1 Env-mediated fusion depends on sequence and accessibility of the gp41 loop region. J. Virol. (2000) 74:2142-2150.
31. LABROSSE B, PLESKOFF O, SOL N, JONES C, HENIN Y, ALIZON M: Resistance to a drug blocking human immunodeficiency virus Type 1 entry (RPR103611) is conferred by mutations in gp41. J. Virol. (1997) 71:8230-8236.
32. DUMONCEAUX J, CHANEL C, VALENTE S, QUIVET L, BRIAND P, HAZAN U: Mutations in the env gene of human immunodeficiency virus Type 1 NDK isolates and the use of African green monkey CXCR4 as a co-receptor in COS-7 cells. J. Gen. Virol. (1999) 80(Part 8):1975-1982.
33. KASHIWADA Y, HASHIMOTO F, COSENTINO LM, CHEN CH, GARRETT PE, LEE KH: Betulinic acid and dihydrobetulinic acid derivatives as potent anti-HIV agents. J. Med. Chem. (1996) 39:1016-1017.
34. SUN IC, KASHIWADA Y, MORRIS-NATSCHKE SL, LEE KH: Plant-derived terpenoids and analogues as anti-HIV agents. Curr. Top. Med. Chem. (2003) 3:155-169.
35. WANG BH, POLYA GM: Selective inhibition of cyclic AMP-dependent protein kinase by amphiphilic triterpenoids and related compounds. Phytochemistry (1996) 41:55-63.
36. RECIO MC, GINER RM, MANEZ S et al.: Investigations on the steroidal anti-inflammatory activity of triterpenoids from Diospyros leucomelas. Planta Med. (1995) 61:9-12.
37. SUN IC, WANG HK, KASHIWADA Y et al.: Anti-AIDS agents. 34. Synthesis and structure-activity relationships of betulin derivatives as anti-HIV agents. J. Med. Chem. (1998) 41:4648-4657.
38. CANNON J: Analog design. In: Burger's Medicinal Chemistry and Drug Discovery, Wolff M (Ed.) John Wiley & Sons, Inc., New York, USA (1994):783.
39. KASHIWADA Y, CHIYO J, IKESHIRO Y et al.: Synthesis and anti-HIV activity of 3-alkylamido-3-deoxy-betulinic acid derivatives. Chem. Pharm. Bull. (2000) 48:1387-1390.
40. RAMBAUT A, POSADA D, CRANDALL KA, HOLMES EC: The causes and consequences of HIV evolution. Nat. Rev. Genet. (2004) 5:52-61.
41. ZHOU J, YUAN X, DISMUKE D et al.: Small-molecule inhibition of human immunodeficiency virus Type 1 replication by specific targeting of the final step of virion maturation. J. Virol. (2004) 78:922-929.
42. SWANSTROM R, WILLS JW: Synthesis, assembly, and processing of viral proteins. Retroviruses (1997):263-334.
43. FREED EO: HIV-1 gag proteins: diverse functions in the virus life cycle. Virology (1998) 251:1-15.
44. VOGT VM: Proteolytic processing and particle maturation. Curr. Top. Microbiol, Immunol. (1996) 214:95-131.
45. KRAUSSLICH HG, SCHNEIDER H, ZYBARTH G, CARTER CA, WIMMER E: Processing of in vitro-synthesized gag precursor proteins of human immunodeficiency virus (HIV) Type 1 by HIV proteinase generated in Escherichia coli. J. Vilrol. (1988) 62:4393-4397.
46. MERVIS RJ, AHMAD N, LILLEHOJ EP et al.: The gag gene products of human immunodeficiency virus Type 1: alignment within the gag open reading frame, identification of posttranslational modifications, and evidence for alternative gag precursors. J. Virol. (1988) 62:3993-4002.
47. ERICKSON-VIITANEN S, MANFREDI J, VIITANEN P et al.: Cleavage of HIV-1 gag polyprotein synthesized in vitro: sequential cleavage by the viral protease. AIDS Res. Hum. Retroviruses (1989) 5:577-591.
48. KAPLAN AH, ZACK JA, KNIGGE M et al.: Partial inhibition of the human immunodeficiency virus type 1 protease results in aberrant virus assembly and the formation of noninfectious particles. J. Virol. (1993) 67:4050-4055.
49. SALZWEDEL K, GOILA-GAUR R, LI F et al.: Selection for and characterization of HIV-1 isolates resistant to the maturation inhibitor PA-457. The 15th International AIDS Conference, Bangkok, Thailand (2004).
50. ZHOU J, CHEN CH, AIKEN C: The sequence of the CA-SP1 junction accounts for the differential sensitivity of HIV-1 and SIV to the small molecule maturation inhibitor 3-O-(3′,3′-dimethylsuccinyl)-betulinic acid. Retrovirology (2004) 1:15.
51. NAMIKAWA R, WEILBAECHER KN, KANESHIMA H, YEE EJ, McCUNE JM: Long-term human hematopoiesis in the SCID-hu mouse. J. Exp. Med. (1990) 172:1055-1063.
52. RABIN L, HINCENBERGS M, MORENO MB et al.: Use of standardized SCID-hu Thy/Liv mouse model for preclinical efficacy testing of anti-human immunodeficiency virus Type 1 compounds. Antimicrob. Agents Chemother. (1996) 40:755-762.
53. ALLAWAY G, BARE J, KILGORE N et al.: The first-in-class maturation inhibitor, PA-457, is a potent inhibitor of HIV replication both in vitro and in vivo. The 25th International AIDS Conference, Bangkok, Thailand (2004).
54. MARTIN D, SMITH P, WILD C, ALLAWAY G: In vitro and in vivo disposition of PA-457, a novel inhibitor of HIV-1 maturation. The 15th International AIDS Conference, Bangkok, Thailand (2004).
55. MARTIN D, BALLOW C, DOTO J, BLUM R, WILD C, ALLAWAY G: The safety, tolerability, and pharmacokinetics of multiple oral doses of PA-457, the first-in-class HIV maturation inhibitor, in healthy volunteers. The 12th Conference on Retroviruses and Opportunistic Infections, MA, USA (2005).
56. MARTIN D, JACOBSON J, SCHURMANN D et al.: PA-457, the first-in-class maturation inhibitor, exhibits antiviral activity following a single oral dose in HIV-1-infected patients. The 12th Conference on Retroviruses and Opportunistic Infections, MA, USA (2005).
57. BARDITCH-CROVO P, DEEKS SG, COLLIER A et al.: Phase I/II trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in human immunodeficiency virus-infected adults. Antimicrob. Agents Chemother. (2001) 45:2733-2739.
58. RICHMAN D, BOZZETTE S, MORTON S et al.: The prevalence of antiretroviral drug resistance in the US. 41st Interscience Conference on Antimicrobrobial Agents Chemotherapy, IL, USA (2001).
59. LABONTE J, LEBBOS J, KIRKPATRICK P: Enfuvirtide. Nat. Rev. Drug Discov. (2003) 2:345-346.
60. SUN IC, SHEN JK, WANG HK, COSENTINO LM, LEE KH: Anti-AIDS agents. 32. Synthesis and anti-HIV activity of betulin derivatives. Bioorg. Med. Chem. Lett. (1998) 8:1267-1272.